Tags : Hemophilia A Without Factor VIII Inhibitors

Roche’s Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients

Tuba Khan June 19, 2019

Shots: The approval is based on HAVEN 3 & 4 studies. The P-III HAVEN 3 study results assessing Hemlibra (qw/q2w) vs episodic FVIII & no prophylaxis in 152 patients with […]readmore

Tags : Hemophilia A Without Factor VIII Inhibitors

Roche’s Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Hemophilia A Without Factor VIII Inhibitors

Roche’s Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company